Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07789483 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

Name: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy — clinical trial record (NCT07789483)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: LTSAFE-ALXN

StatusNot Yet Recruiting

PhasePhase 3

SponsorAlexion Pharmaceuticals, Inc.

Started2027-11-23

View on ClinicalTrials.gov ↗

The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.

Trial Details

NCT Number	NCT07789483
Lead Sponsor	Alexion Pharmaceuticals, Inc.
Conditions	Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Enrollment	1,180 participants
Start Date	2027-11-23
Primary Completion	2030-07-11 (estimated)
Study Completion	2030-07-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-28